Abstract 423P
Background
CGP through Next-Generation Sequencing (NGS) detects a broad spectrum of therapeutic, prognostic, and predictive biomarkers - tumor mutational burden (TMB), microsatellite instability (MSI) burden, somatic BRCA (sBRCA), and homologous recombination repair genes (HRR) providing a more cost-efficient and tissue-preserving approach than serial single-biomarker analysis.
Methods
1000 biopsy proven cancer patients at HCG cancer centre, were profiled using Illumina TruSight Oncology 500 (TSO500) assay on a NextSeq2000 in an IRB-approved study. The NGS findings were discussed in the molecular tumor board (MTB) and recommendations were documented.
Results
A total of 1735 genomic alterations were detected (≥1mutations/sample). CGP identified genetic alterations with therapeutic and prognostic implications in 80% of patients (Tier I- 44%, Tier II-54%, Tier III-14%) . CGP revealed a higher number of druggable genes (48%) than small panels (14%). TMB and MSI-H were observed in 15% and 1% of the cohort respectively, started on IO and are on follow-up. HRR pathway alterations including sBRCA were detected in 15% of cohort, initiated on platinum or PARP inhibitors and achieved a complete pathological response . Other significant alterations detected were EGFR, KRAS/ BRAF, PIK3CA, cKIT, PDGFRA, ARID1A, ARID2, and FGFR, NTRK. RNA sequencing yielded 64 RNA alterations (48 translocations and 16 splice variants). Androgen receptor splice variants were observed in >35% of prostate carcinoma patients for whom androgen inhibitors were discontinued and taxane therapy was initiated. Other frequent fusions detected were: TMPRSS-ERG, RPS6KB1-VMP1, EML4-ALK, NTRK, PDGFRA and EWSR. CGP also revealed many resistance mechanism genes across cancer spectrum which enabled change in 2nd/3rd-line therapy. Table: 423P
Clinical management of the main cancer types informed by actionable biomarkers detected by CGP
Cancer type | Tier I+Tier II % | MTB recommendations % | Patients assigned to approved therapies, % |
Breast | >80% | 40% | 30% |
Gynecological | >85% | 40% | 30% |
Lung | >88% | 90% | 80% |
H&N | 60% | 10% | 5% |
GU | 73% | 25% | 15% |
GI | 48% | 80% | 70% |
Conclusions
CGP identified more druggable gene aberrations across diverse cancers enabling optimizing personalized cancer treatment in Indian patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B.S. Ajaikumar: Financial Interests, Institutional, Member of Board of Directors, Executive Chairman: HCG. All other authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract